Luigi M. Grimaldi

Cefalu, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Correction: Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.

Correction: Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.

Journal: Journal of neurology
Published: May 18, 2026

Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial.

Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial.

Journal: Parkinsonism & related disorders
Published: April 27, 2026

Probable tirzepatide-associated limbic encephalitis with status epilepticus in a patient with extreme obesity: a case report.

Probable tirzepatide-associated limbic encephalitis with status epilepticus in a patient with extreme obesity: a case report.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: December 19, 2025

Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.

Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.

Journal: Journal of neurology
Published: November 18, 2025

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.

Journal: Journal of neurology
Published: April 19, 2023

Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study).

Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study).

Journal: Current neuropharmacology
Published: July 17, 2022

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.

Journal: Journal of neurology
Published: March 01, 2021

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: April 16, 2020

Incidence of multiple sclerosis in the province of Catania. A geo-epidemiological study.

Incidence of multiple sclerosis in the province of Catania. A geo-epidemiological study.

Journal: Environmental research
Published: October 22, 2019

Anti-inflammatory and cognitive effects of interferon-β1a (IFNβ1a) in a rat model of Alzheimer's disease.

Anti-inflammatory and cognitive effects of interferon-β1a (IFNβ1a) in a rat model of Alzheimer's disease.

Journal: Journal of neuroinflammation
Published: August 13, 2018

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: August 06, 2018

The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy.

The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy.

Journal: Medical science monitor : international medical journal of experimental and clinical research
Published: September 03, 2017
Showing 1-12 of 16

Last Updated: 09/26/2026